Immunization strategies for the prevention of pneumovirus infections

References

• Pelletier AJ, Mansbach JM, Camargo CA. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics118(6), 2418–2423 (2006).
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Guiterrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics82, 199–203 (1988).
   PubMed Web of Science ®Google Scholar
• Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants less than 32 weeks gestation. Pediatrics88, 527–532 (1991).
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Hall CB, Suffin SC et al. Respiratory syncytial virus infection in infants with congenital heart disease. N. Engl. J. Med.307, 397–400 (1982).
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherrill D, Morgan WJ et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet354(9178), 541–545 (1999).
   PubMed Web of Science ®Google Scholar
• Bisgaard A. Randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med.167, 379–383 (2003).
   PubMed Web of Science ®Google Scholar
• Csonka P, Kaila M, Laippala P et al. Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J. Pediatr.143(6), 725–730 (2003).
   PubMed Web of Science ®Google Scholar
• Garrison MM, Christakis DA, Harvey E et al. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics105(4), E44 (2000).
   PubMed Web of Science ®Google Scholar
• Turner TW, Evered LM. Evidence-based emergency medicine/systematic review abstract: are bronchodilators effective in bronchiolitis? Ann. Emerg. Med.42, 709–711 (2003).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol.89(4), 405–421 (1969).
   PubMed Web of Science ®Google Scholar
• Prince GA, Curtis SJ, Yim KC et al. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with lot 100 or a newly prepared reference vaccine. J. Gen. Virol.82(12), 2881–2888 (2001).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Wyde PR, Castleman WL et al. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine11(14), 1415–1423 (1993).
   PubMed Web of Science ®Google Scholar
• Ponnuraj EM, Hayward AR, Raj A et al. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine. J. Gen. Virol.82(11), 2663–2674 (2001).
   PubMed Web of Science ®Google Scholar
• Ponnuraj EM, Springer J, Hayward AR et al. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J. Infect. Dis.187(8), 1257–1263 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Parker RA, Johnson JE et al. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol.170, 2037–2045 (2003).
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Olszewska W, Wang B et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med.12, 905–907 (2006).
   PubMed Web of Science ®Google Scholar
• Durbin AP, Karron RA. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin. Infect. Dis.37, 1668–1677 (2003).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Grace S, Jewell A et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J.15(1), 23–31 (1996).
   PubMed Web of Science ®Google Scholar
• Power UF, Plotnicky H, Blaecke A et al. The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine22(2), 168–176 (2003).
   PubMed Web of Science ®Google Scholar
• Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev. Med. Virol.14(3), 149–168 (2004).
   PubMed Web of Science ®Google Scholar
• The PREVENT study group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics99(1), 93–99 (1997).
   PubMed Web of Science ®Google Scholar
• Simoes EA, Sondheimer HM, Top FH Jr et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J. Pediatr.133, 492–499 (1998).
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics102(3), 531–537 (1998).
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr.143(4), 532–540 (2003).
   PubMed Web of Science ®Google Scholar
• Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics112(6), 1447–1452 (2003).
   PubMed Web of Science ®Google Scholar
• MedImmune Inc. Infinity and medimmune announce promising biological activity of anti-Hsp90 compound in Phase I GIST trial. 7th November 2006 (Press release).
   Google Scholar
• Parrot RH, Kim HW, Arrobio JO. Epidemiology of respiratory syncytial virus infection in Washington D.C. II. Infection and disease with respect to age, immunologic status, race and age. Am. J. Epidemiol.98, 289–300 (1973).
   PubMed Web of Science ®Google Scholar
• Beem M, Egerer R, Anderson J. Respiratory syncytial virus neutralizing antibodies in persons residing in Chicago, Illinois. Pediatrics34, 761–770 (1964).
   PubMed Web of Science ®Google Scholar
• Lamrecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J. Infect. Dis.134, 211–217 (1976).
   PubMed Web of Science ®Google Scholar
• Wright AL, Taussig LM, Ray CG et al. The Tuscon Children’s Respiratory Study. II. Lower respiratory tract illness in the first year of life. Am. J. Epidemiol.129, 1232–1246 (1989).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE et al. Risk of RSV infection in infants from low risk families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr.98, 708–715 (1981).
   PubMed Web of Science ®Google Scholar
• Ogilvie MM, Vathenen AS, Radford M et al. Maternal antibody and RSV infection in infants. J. Med. Virol.17, 263–271 (1981).
   Web of Science ®Google Scholar
• Wang EE, Law BJ, Robinson JL et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) Study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics99, E9 (1997).
   PubMed Web of Science ®Google Scholar
• Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of RSV purified fusion protein-2 vaccine in pregnant women. Vaccine21, 3465–3467 (2003).
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Hotomi M, Billal DS et al. Maternal intranasal immunization with outer membrane protein P6 maintains specific antibody level of derived offspring. Vaccine24, 5294–5299 (2006).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Smith B, Clarke K et al. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Hum. Vaccin.1, 37–42 (2005).
   PubMed Web of Science ®Google Scholar
• Collins PL, Hill MG, Camargo E et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5´ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl Acad. Sci. USA92(25), 11563–11567 (1995).
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Crowe JE et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis.176(6), 1428–1436 (1997).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis.182, 1331–1342 (2000).
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis.191, 1093–1104 (2005).
   PubMed Web of Science ®Google Scholar
• Karron RA, Makhene M, Gay K et al. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr. Infect. Dis. J.15, 650–654 (1996).
   PubMed Web of Science ®Google Scholar
• Lee MS, Greenberg DP, Yeh SH et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. J. Infect. Dis.184, 909–913 (2001).
   PubMed Web of Science ®Google Scholar
• Schmidt AC, McAuliffe JM, Murphy BR et al. Recombinant bovine/human parainfluenza virus type 3 (b/hHPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol.75(10), 4594–4603 (2001).
   PubMed Web of Science ®Google Scholar
• Tang RS, MacPhail M, Schickli JH et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J. Virol.78(20), 11198–11207 (2004).
   PubMed Web of Science ®Google Scholar
• Doggett JE, Taylor-Robinson D, Gallop RGC. A study of an inhibitor in bovine serum against respiratory syncyital virus. Arch. Gesamte Virusforsch.23, 126–137 (1968).
   PubMedGoogle Scholar
• Paccaud MF, Jacquier C. A respiratory syncytial virus of bovine origin. Arch. Gesamte Virusforsch.30(4), 327–342 (1970).
   PubMedGoogle Scholar
• Rosenberg HF, Bonville CA, Easton AJ et al. The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention. Pharmacol. Ther.105, 1–6 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Poel WH, Kramps JA, Middel WGJ et al. Respiratory syncytial virus infections in human beings and in cattle. J. Infect. Dis.29, 215–228 (1994).
   Google Scholar
• Baker JC, Ellis JA, Clark EG. Bovine respiratory syncytial virus. Vet. Clin. North Am. Food Anim. Pract.13, 425–454 (1997).
   PubMed Web of Science ®Google Scholar
• Valarcher JF, Schelcher F, Bourhy H. Evolution of bovine respiratory syncytial virus. J. Virol.74(22), 10714–10728 (2000).
   PubMed Web of Science ®Google Scholar
• Larsen LE, Tjorjnehoj K, Viruff B. Extensive sequence divergence among bovine respiratory syncytial virus isolated during recurrent outbreaks in closed herds. J. Clin. Microbiol.38(11), 4222–4227 (2000).
   PubMed Web of Science ®Google Scholar
• Kimman TG, Westenbrink F. Immunity to human and bovine respiratory syncytial virus. Arch. Virol.112, 1–25 (1990).
   PubMed Web of Science ®Google Scholar
• Bryson DG, McNulty MS, Logan EF et al. Respiratory syncytial virus pneumonia in young calves: clinical and pathologic findings. Am. J. Vet. Res.44, 1648–1655 (1983).
   PubMed Web of Science ®Google Scholar
• Bryson DG. Necropsy findings associated with BRSV pneumonia. Vet. Med.88, 6–9 (1993).
   Google Scholar
• Kimman TG, Straver PJ, Zimmer GM. Pathogenesis of naturally acquired bovine respiratory syncytial virus infection in calves: morphologic and serologic findings. Am. J. Vet. Res.50, 684–693 (1989).
   PubMed Web of Science ®Google Scholar
• West K, Petrie L, Haines DM et al. The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection of calves. Vaccine17, 809–820 (1999).
   PubMed Web of Science ®Google Scholar
• West KH, Petrie L, Konoby C et al. The efficacy of modified live bovine respiratory syncytial virus vaccines in experimentally infected calves. Vaccine18, 907–919 (2000).
   Web of Science ®Google Scholar
• Antonis AF, Claassen EA, Hensen EJ et al. Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection. Vaccine24(10), 1551–1561 (2006).
   PubMed Web of Science ®Google Scholar
• Ellis JA, West KH, Konoby C et al. Efficacy of an inactivated respiratory syncytial virus vaccine in calves. J. Am. Vet. Med. Assoc.218(12), 1973–1980 (2001).
   PubMed Web of Science ®Google Scholar
• Ellis JA, Gow S, West KH et al. Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves. Can. Vet. J.46, 155–162 (2005).
   PubMed Web of Science ®Google Scholar
• Van Donkersgoed J, Janzen ED, Townsend HG et al. Five field trials on the efficacy of a bovine respiratory syncytial virus vaccine. Can. Vet. J.31, 93–100 (1990).
   PubMed Web of Science ®Google Scholar
• Hansen DE, Syvrud R, Armstrong D. Effectiveness of a respiratory syncytial virus vaccine in reducing the risk of respiratory disease. Agri. Pract.13, 19–23 (1992).
   Google Scholar
• Ferguson JD, Galligan DT, Cortese V. Milk production and reproductive performance in dairy cows given bovine respiratory syncytial virus vaccine prior to parturition. J. Am. Vet. Med. Assoc.210, 1779–1783 (1997).
   PubMed Web of Science ®Google Scholar
• Kimman TG, Zimmer GM, Westenbrink F et al. Epidemiologic study of bovine respiratory syncytial virus infection in calves: influence of maternal antibodies on the outcome of disease. Vet. Rec.123, 104–109 (1988).
   PubMed Web of Science ®Google Scholar
• Belknap EB, Baker JC, Patterson JS et al. The role of passive immunity in bovine respiratory syncytial virus infected calves. J. Infect. Dis.163, 470–476 (1991).
   PubMed Web of Science ®Google Scholar
• Baker JC, Ames TR, Markham RJF. A seroepidemiologic study of bovine respiratory syncytial virus in a dairy herd. Am. J. Vet. Res.47, 240–245 (1986).
   PubMed Web of Science ®Google Scholar
• Hagglund S, Hu KF, Larsen LE et al. Bovine respiratory syncytial virus ISCOMs – protection in the presence of maternal antibodies. Vaccine23, 646–655 (2004).
   PubMed Web of Science ®Google Scholar
• Patel J, Didlick S. Evaluation of efficacy of an inactivated vaccine against bovine respiratory syncytial virus in calves with maternal antibodies. Am. J. Vet. Res.65, 417–421 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas LH, Cook RS, Wyld SG et al. Passive protection of gnotobiotic calves using monoclonal antibodies directed at different epitopes on the fusion protein of bovine respiratory syncytial virus. J. Infect. Dis.177, 874–880 (1998).
   PubMed Web of Science ®Google Scholar
• Kimman TG, Westenbrink F, Schreuder BEC et al. Local and systemic antibody response to bovine respiratory syncytial virus infection in calves with or without maternal antibodies. J. Clin. Microbiol.25, 1097–1106 (1987).
   PubMed Web of Science ®Google Scholar
• Woolums AR, Brown CC, Cole JC et al. Effect of a single intranasal dose of modified-live bovine respiratory syncytial virus vaccine on resistance to subsequent viral challenge in calves. Am. J. Vet. Res.65, 363–372 (2004).
   PubMed Web of Science ®Google Scholar
• Miao C, Woolums AR, Zarlenga DS et al. Effect of a single intranasal dose of modified-live bovine respiratory syncytial virus vaccine on cytokine messenger RNA expression following viral challenge in calves. Am. J. Vet. Res.65(6), 725–733 (2004).
   PubMed Web of Science ®Google Scholar
• Vangeel I. Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in three-week old calves experimentally challenged with BRSV. Br. Cat. Vet. Assoc. J.13, 263–271 (2005).
   Google Scholar
• Ellis JA, Gow S, West KH et al. Response of calves to challenge exposure with virulent BRSV following intranasal administration of parenteral vaccines. J. Am. Vet. Med. Assoc.230(2), 233–243 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor G, Bruce C, Barbet AF et al. DNA vaccination against respiratory syncytial virus in young calves. Vaccine23(10), 1242–1250 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt U, Beyer J, Polster U et al. Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. J. Virol.76(23), 123555–123559 (2004).
   Google Scholar
• Valarcher JF, Furze J, Wyld S et al. Role of α/β interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J. Virol.77(15), 8426–8439 (2003).
   PubMed Web of Science ®Google Scholar
• Kim H, Canchola JG, Brandt G et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89, 422–424 (1969).
   PubMed Web of Science ®Google Scholar
• Wellemans G, Leunen J. Le virus respiratoire syncytial et les troubles respiratoires des bovines.Ann. Med. Vet.119, 359–369 (1975).
   Google Scholar
• Gershwin LJ, Schelegle FS, Gunther RA et al. A bovine model of vaccine-enhanced respiratory syncytial virus pathophysiology. Vaccine16, 1225–1236 (1998).
   PubMed Web of Science ®Google Scholar
• Kalina WV, Wollums AR, Berghaus RD et al. Formalin-inactivated bovine RSV vaccine enhances a Th2-mediated immune response in infected calves. Vaccine22(11–12), 1465–1474 (2004).
   PubMed Web of Science ®Google Scholar
• Kalina WV, Wollums AR, Gershwin LJ. Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchiolar lavage fluid and disease outcome in experimentally infected calves. Vaccine23(37), 4625–4630 (2005).
   PubMed Web of Science ®Google Scholar
• Antonis A, Schrijver RS, Daus F et al. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J. Virol.77, 12067–12073 (2003).
   PubMed Web of Science ®Google Scholar
• Mohanty SB, Rockemann DD, Davidson JP et al. Effect of vaccinal serum antibodies on bovine respiratory syncytial virus infection in calves. Am. J. Vet. Res.42, 881–883 (1981).
   PubMed Web of Science ®Google Scholar
• Schreiber P, Matheise JP, Dessy F et al. High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian blue calves previously vaccinated with an inactivated vaccine. J. Vet. Med. Infect. Dis. Vet. Public Health B.47, 535–550 (2000).
   PubMed Web of Science ®Google Scholar
• Larsen LE, Tegtmeier C, Pedersen B. Bovine respiratory syncytial virus (BRSV) pneumonia in beef calf herds despite vaccination. Acta Vet. Scand.42(1), 113–121 (2001).
   PubMed Web of Science ®Google Scholar
• Peters AR, Thevasagayam SJ, Wiseman A et al. Duration of immunity of a quadrivalent vaccine against respiratory dieases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves. Prevent. Vet. Med.66(14), 63–77 (2004).
   PubMed Web of Science ®Google Scholar
• Kimman TG, Sol J, Westenbrink F et al. A severe outbreak of respiratory tract disease associated with bovine respiratory syncytial virus probably enhanced by vaccination with modified live vaccine. Vet. Q.11, 250–253 (1989).
   PubMed Web of Science ®Google Scholar
• Easton AJ, Domachowske JB, Rosenberg HF. Animal pneumoviruses: molecular genetics and pathogenesis. Clin. Microbiol. Rev.17, 390–412 (2004).
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Bonville CA, Rosenberg HF. Gene expression in epithelial cells in response to pneumovirus infection. Respir. Res.2, 225–233 (2001).
   PubMed Web of Science ®Google Scholar
• Cook PM, Eglin RP, Easton AJ. Pathogenesis of pneumovirus infections in mice: detection of pneumonia virus of mice and human respiratory syncytial virus mRNA in lungs of infected mice by in situ hybridization. J. Gen.Virol.79, 2411–2417 (1998).
   PubMed Web of Science ®Google Scholar
• Bonville CA, Bennett NJ, Koehnlein M et al. Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. Virology349, 87–95 (2006).
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Bonville CA, Gao JL et al. The chemokine macrophage-inflammatory protein-1α and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J. Immunol.165, 2677–2682 (2000).
   PubMed Web of Science ®Google Scholar
• Ellis JA, Martin BV, Waldner C et al. Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-γ receptor deficient mice. Vaccine25, 1085–1095 (2007).
   PubMed Web of Science ®Google Scholar
• Claassen EA, vander Kant PA, Rychnavska ZS et al. Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection. J. Immunol.175, 6597–6604 (2005).
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Bonville CA, Ali-Ahmad D et al. Glucocorticoid administration accelerates mortality of pneumovirus-infected mice. J. Infect. Dis.184, 1518–1523 (2001).
   PubMed Web of Science ®Google Scholar
• Randolph AG, Wang EEL. Ribavirin for respiratory syncytial virus lower respiratory tract infection: a systematic overview. Arch. Pediatr. Adolesc. Med.150, 942–947 (1996).
   PubMed Web of Science ®Google Scholar
• Bonville CA, Easton AJ, Rosenberg HF et al. Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J. Virol.77, 1237–1244 (2003).
   PubMed Web of Science ®Google Scholar
• Bonville CA, Lau VK, DeLeon JM et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol.78(15), 7984–7989 (2004).
   PubMed Web of Science ®Google Scholar
• Thorpe LC, Easton AJ. Genome sequence of the non-pathogenic strain 15 of pneumonia virus of mice and comparison with the genome of the pathogenic strain J3666. J. Gen. Virol.86, 159–169 (2005).
   PubMed Web of Science ®Google Scholar
• Krempl CD, Lamirande EW, Collins PL. Complete sequence of the RNA genome of pneumonia virus of mice (PVM). Virus Genes30, 237–249 (2005).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Madhi SA et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect. Dis.193, 573–581 (2006).
   PubMed Web of Science ®Google Scholar
• Anh DB, Faisca P, Desmecht DJ. Differential resistance/susceptibility patterns to pneumovirus infection among inbred mouse strains. Am. J. Physiol. Lung Cell Mol. Physiol.291, L426–L435 (2006).
   Web of Science ®Google Scholar